Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients

HIV Clinical Trials

Volumn 4, Issue 5, 2003, Pages 330-336

  Clevenbergh, Philippe ^a,c   Garraffo, R ^b   Dellamonica, P ^b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c Outpatients Clinique   (France)

Author keywords

Antiretroviral drugs; HIV infection; Plasma concentration; Plasma lipids; Therapeutic drug monitoring

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CHOLESTEROL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; OXAZINES; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TRIGLYCERIDES;

EID: 0142155151     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/8TXF-P814-8JPF-7TRY     Document Type: Article

References (19)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-58
2. Meng Q, Lima JA, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J. 2002;144:642-648.
3. Cheseaux JJ, Jotterand V, Aebi C, et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr. 2002;30:288-293.
4. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050-2056.
5. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS. 2002;16:2311-2315.
6. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, for The Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15:2407-2414.
7. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS. 2002;16:1383-1389.
8. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, for The Spanish Lipodystrophy Group. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr. 2001;27:229-236.
9. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis. 2000;31:1266-1273.
10. Roge BT, Katzenstein TL, Gerstoft J. Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. Scand J Infect Dis. 2001;33:306-311.
11. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
12. Wensing AM, Reedijk M, Richter C, Boucher CA, Borleffs JC. Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. AIDS. 2001;15:2191-2193.
13. Sanne I, Piliero, P, Squires K, Thiry A, Schnittman S, AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18-29.
14. Dumon C, Solas C, Thuret I, et al. Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection. Ther Drug Monit. 2000;22:402-408.
15. Routy JP, Smith GH, Blank DW, Gilfix BM. Plasmapheresis in the treatment of an acute pancreatitis due to protease inhibitor-induced hypertriglyceridemia. J Clin Apheresis. 2001;16:157-159.
16. Lister RK, Youle M, Nair DR, Winder AF, Rustin MH. Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet. 1999;353:1678.
17. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglycerides/low HDL levels in treated patients. AIDS. 2001;15:2397-2406.
18. Kumar P, Rodriguez-French A, Thompson M, et al. Prospective study of hyperlipidemia in ART-naïve subjects taking Combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T /lamivudine (3TC)/NFV (ESS40002). In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Abstract 33.
19. Gallant J, Staszewski S, Pozniak A, et al. Favorable lipid and mitochondrial (mt) DNA profile for tenofovir disoproxil fumarate (TDF) compared to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral therapy (ART)-naive patients: a 48 week interim analysis. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2002; San Diego, California. Abstract LB-2.